Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
Journal of Clinical Oncology · 01.07.2026 · 44 (19) · 1833-1844
DOI: 10.1200/jco-25-03026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2026. Verfasst von Cassio Murilo Hidalgo-Filho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 153 Literaturangaben.
Abstract (Originalsprache)
Acquired resistance (AR) to immune checkpoint inhibitors (ICIs) remains a major obstacle to durable clinical benefit in non–small cell lung cancer (NSCLC). Emerging after initial responses, AR reflects tumor evolution, immune escape, and metabolic reprogramming. Key mechanisms may include impaired antigen presentation (β2-microglobulin, human leukocyte antigen mutations), T-cell exhaustion, and remodeling of the tumor microenvironment (TME). In this review, we summarize the current understanding of ICIs resistance and highlight therapeutic strategies under investigation to overcome it. Novel approaches include next-generation ICIs targeting TIGIT and LAG-3, epigenetic modulators (HDAC, DNMT inhibitors), and metabolic agents relevant to STK11 and KEAP1 mutations. Additional strategies aim to reprogram the TME through AXL or multikinase inhibition, tumor-treating fields, and cytokine- and/or gene-based therapies. Cellular immunotherapies (tumor-infiltrating lymphocytes, T-cell receptors, chimeric antigen receptor-T), antibody-drug conjugates, and vaccines offer complementary means to restore antitumor immunity. Advancing the field will require biomarker-driven patient selection and rational combinations to overcome AR and achieve more durable, personalized immunotherapy outcomes in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
- Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil.
- Oncologia Clinica, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
ORCID-Profile: Cassio Murilo Hidalgo-Filho, Valentina Santo, Eleonora Gariazzo, Mihaela Aldea, François-Xavier Danlos, Gilberto de Castro Junior, Biagio Ricciuti
Zitieren
APA
Hidalgo-Filho, C. M., Santo, V., Gariazzo, E., Aldea, M., Pecci, F., Danlos, F. X., de Castro Junior, G., & Ricciuti, B. (2026). Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies. Journal of Clinical Oncology, 44(19), 1833-1844. https://doi.org/10.1200/jco-25-03026
Vancouver
Hidalgo-Filho CM, Santo V, Gariazzo E, Aldea M, Pecci F, Danlos FX, et al. Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies. Journal of Clinical Oncology. 2026;44(19):1833-1844. doi:10.1200/jco-25-03026
BibTeX
@article{HidalgoFilho2026,
author = {Hidalgo-Filho, Cassio Murilo and Santo, Valentina and Gariazzo, Eleonora and Aldea, Mihaela and Pecci, Federica and Danlos, François-Xavier and de Castro Junior, Gilberto and Ricciuti, Biagio},
title = {Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {19},
pages = {1833--1844},
doi = {10.1200/jco-25-03026}
}
EUVIMED